

Factsheet

August 2016

Engineering the Medicines of Tomorrow

The Company

MorphoSys is a leading biotechnology company developing therapeutic antibodies. The Company uses its proprietary antibody and peptide technologies HuCAL, Ylanthia and LanthioPep to develop innovative drug candidates together with partners and on its own account. Currently, there are more than 100 therapeutic programs in development that are to be used for patients with severe diseases like Alzheimer's disease, cancer, infectious, cardiovascular or inflammatory diseases in the future. Around a quarter of all development programs are in clinical trials.

Strategy

The business strategy of MorphoSys builds on two pillars. The Partnered Discovery segment operates in partnerships with renowned biotechnology and pharmaceutical companies, applying the company's proprietary technologies to generate new drug candidates. The second segment, Proprietary Development, develops new therapeutic candidates on its own responsibility. The focus is on indications such as oncology, inflammatory and autoimmune diseases as well as fibrotic diseases. Each of these programs is pursuing an innovative approach to diseases that are currently inadequately treated. The Company's proprietary portfolio will also be extended externally through in-licensing, acquisitions and co-development agreements. In 2012, MorphoSys launched its "Innovation Capital" initiative through which the Company invests in promising startups with technologies and product candidates being close to its areas of interest.

Partnering

MorphoSys is consistently on the lookout for partnerships with organizations having complementary expertise, technologies, compounds or targets. We are interested in establishing collaborations and co-development alliances to join forces and bringing new therapies to patients.

In the past, the MorphoSys team has successfully utilized their antibody technologies to generate one of the industry's largest therapeutic pipelines. We have a track record in partnerships and collaborations and have successfully developed antibody therapeutics in inflammation and oncology from the target to phase II proof of concept. We have a biotechnological mindset and our dedication is to become a fully integrated biopharmaceutical company including late stage clinical development and marketing of its own drugs. We are selective in the number and type of alliances that we participate in, thus enabling us to provide a high level of attention to each partner and product.

MORPHOSYS AG

- **Stock Exchange** Frankfurt, Germany, TecDAX 30
- **Security Code Number** MOR/663200 (ISIN: DE 0006632003)
- **No. of Employees (June 30, 2016)** 361
- **Financial Guidance 2016**
 - Group Revenues € 47 to € 52 million
 - Group EBIT € -58 to € -68 million
- **Management Board**
 - Dr. Simon E. Moroney, Chief Executive Officer
 - Jens Holstein, Chief Financial Officer
 - Dr. Arndt Schottelius, Chief Development Officer
 - Dr. Marlies Sproll, Chief Scientific Officer

MorphoSys AG
Lena-Christ-Str. 48
82152 Martinsried / Planegg
Germany

Phone: +49 (0) 89 899 27-0
Fax: +49 (0) 89 899 27-222
Email: info@morphosys.com
Website: www.morphosys.com

Product Pipeline*

Program / Partner	Indication	Discovery	Preclinic	Phase 1	Phase 2	Phase 3
Guselkumab (CNT01959), Janssen	Psoriasis					
Gantenerumab, Roche	Alzheimer's disease					
MOR208	ALL, CLL, NHL					
MOR202	Multiple myeloma					
MOR103/GSK3196165, GSK	Inflammation					
Anetumab Ravtansine (BAY94-9343), Bayer	Solid tumors					
Bimagrumab (BYM338), Novartis	Musculoskeletal diseases					
BHQ880, Novartis	Multiple myeloma					
BPS804, Mereo/Novartis	Brittle bone syndrome					
CNT03157, Janssen	Inflammation					
CNT06785, Janssen	Inflammation					
Elgertumab (LJM716), Novartis	Cancer					
Tarextumab (OMP-59R5), OncoMed	Solid tumors					
Tesidolumab (LFG316), Novartis	Eye diseases					
VAY736, Novartis	Inflammation					
Utomilumab (PF-05082566), Pfizer	Solid tumors					
MOR209/ES414, Emergent	Prostate cancer					
MOR106, Galapagos	Inflammation					
BAY1093884, Bayer	Hemophilia					
BI-836845, BI	Solid tumors					
NOV-7, Novartis	Eye diseases					
NOV-8, Novartis	Inflammation					
NOV-9, Novartis	Diabetic eye diseases					
NOV-10, Novartis	Cancer					
NOV-11, Novartis	Blood disorders					
NOV-12, Novartis	Prevention of thrombosis					
Vantictumab (OMP-18R5), OncoMed	Solid tumors					
MOR107 (LP2)	Fibrosis					
Immuno-oncology program, Immatics	Cancer					90 Partnered Programs
Immuno-oncology program, Merck	Cancer					13 MOR Programs
6 MOR programs	Various					1 Outlicensed Program

In addition, 23 partnered programs in preclinic, and 45 partnered programs in discovery

* Most advanced development stage

Key Programs

MOR208

MOR208 is a monoclonal antibody that has been in-licensed from Xencor targeting the antigen CD19. The antibody possesses an optimized Fc portion, which further enhances its ability to kill malignant B cells. The program is currently being evaluated in phase 2 trials in patients with DLBCL and CLL.

MOR202

MOR202 is a HuCAL antibody directed against CD38. MOR202 is currently being tested in a phase 1/2a trial in patients with relapsed/refractory multiple myeloma. This trial includes combination cohorts with lenalidomide and pomalidomide.

MOR209/ES414 (co-development with Emergent)

MOR209/ES414 is an anti-PSMA/anti-CD3 bi-specific antibody that is being co-developed with Emergent. The immunotherapeutic protein activates the patients' T cell immunity specifically against prostate cancer cells expressing Prostate Specific Membrane Antigen (PSMA). The program is currently in a phase 1 trial.

MOR106 (co-development with Galapagos)

MOR106 is a Ylanthia antibody for treatment of inflammatory diseases. MOR106 arises from the alliance initiated by Galapagos and MorphoSys in 2008, in which both companies contribute their core technologies and expertise. The program is currently in a phase 1 trial.

MOR103 (outlicensed to GSK)

MOR103 is a HuCAL antibody directed against GM-CSF. In June 2013, MorphoSys signed a worldwide agreement with GSK for the further development and commercialization of MOR103. MOR103 is currently in a phase 2b trial in rheumatoid arthritis, and in a phase 2a trial in osteoarthritis of the hand.

Anetumab Ravtansine (Bayer HealthCare)

Anetumab Ravtansine, an antibody-drug conjugate (ADC) targeting mesothelin, is a potential new treatment for mesothelioma developed by Bayer using MorphoSys's HuCAL technology. It is currently in several clinical phase 1 trials as well as in phase 2 trials, designed to support registration of the compound.

Guselkumab (Janssen)

Guselkumab is a HuCAL antibody specific to IL23p19 and is developed by Janssen Biotech/Johnson & Johnson. The program is currently in several phase 3 clinical trials in psoriasis, and in a phase 2 trial in psoriatic arthritis.

Gantenerumab (Roche)

Gantenerumab is a HuCAL-antibody developed by Roche for Alzheimer's disease. The compound, which aims at the reduction of amyloid plaques in the brain, is currently being evaluated in two phase 3-trials in patients with early symptoms of the disease.